Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Rigel Pharmaceuticals Inc
Revenue
Rigel Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
|
Revenue
$116.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
21%
|
CAGR 10-Years
32%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Rigel Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Rigel Pharmaceuticals Inc
Breakdown by Segments
Rigel Pharmaceuticals Inc
See Also
What is Rigel Pharmaceuticals Inc's Revenue?
Revenue
116.9m
USD
Based on the financial report for Dec 31, 2023, Rigel Pharmaceuticals Inc's Revenue amounts to 116.9m USD.
What is Rigel Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
32%
Over the last year, the Revenue growth was -3%. The average annual Revenue growth rates for Rigel Pharmaceuticals Inc have been 2% over the past three years , 21% over the past five years , and 32% over the past ten years .